Inhibitor Therapeutics Inc INTI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.07
- Day Range
- $0.07–0.07
- 52-Week Range
- $0.01–0.30
- Bid/Ask
- $0.05 / $0.15
- Market Cap
- $11.78 Mil
- Volume/Avg
- 400 / 16,699
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.inhibitortx.com
Valuation
|
Metric
|
INTI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.23 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
INTI
Financial Strength
|
Metric
|
INTI
|
|---|---|
Quick Ratio | 13.29 |
Current Ratio | 13.45 |
Interest Coverage | — |
Quick Ratio
INTI
Profitability
|
Metric
|
INTI
|
|---|---|
Return on Assets (Normalized) | −29.23% |
Return on Equity (Normalized) | −43.15% |
Return on Invested Capital (Normalized) | −48.02% |
Return on Assets
INTI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sqnqxrtck | Qclht | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xvxgngff | Vwzjmhx | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mkjjnyfg | Wydnpjv | $98.1 Bil | |
MRNA
| Moderna Inc | Wjbcjgfk | Qxg | $39.1 Bil | |
ARGX
| argenx SE ADR | Fkxcnjt | Rhvv | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Wznjbgnx | Gxqm | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gqhrhpft | Zfpmhq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pkxdvjt | Xgthnh | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zgrwpsnzk | Ddfmzml | $12.5 Bil | |
INCY
| Incyte Corp | Nssbkvww | Rwspb | $11.9 Bil |